Category Archives: Non classé

Our technological research platform VirNext is very proud of the spin-off VirexpR which has just reached a major step in its technological and strategic development plan. Thanks to its partner ASPIDA for the joint design and realization of this unique test bench in Europe which will allow VirexpR to position itself as an international reference in the management of microbiological and virological environmental pollution, and indoor air quality in confined spaces, whose health,...

The VirPath laboratory, Virnext and the LVMC Molecular and Cellular Virology Laboratory of the CHU de Québec-Université Laval Research Centre, are combining their strengths in the research of respiratory viral infections with the creation of RespiVir France - Canada, an International Associated Laboratory within the partnership framework of Université Claude Bernard Lyon 1 and Université Laval. The public announcement took place in Quebec City on 11 October 2022 in the presence of Ms EugÃ...

The emergence of SARS-CoV-2 have profoundly altered the epidemiology of major seasonal respiratory viruses (influenza, respiratory syncytial virus, human metapneumovirus and human rhinovirus). In this study, we studied and compare the mutual interactions between these pathogens in reconstituted human epithelial airway models (MucilAir®) by exploring different infection and superinfection scenarios. Our results suggest that the virus type and sequence of infections, with the specific nature of t...

This study reports that almost 5% of patients with critical influenza pneumonia studied internationally (cohort of 279 patients) had auto-Abs neutralizing IFN-α2 alone or with IFN-ω. By performing functional assays in our predictive models of influenza infection in reconstituted Human Airway Epithelium (HAE MucilAir), we further demonstrated that IFN-α2 treatment or IAV infection induced the expression of IFN-stimulated genes (ISGs), and that this expression was blocked by auto-Ab–positive...

The invention relates to the use of the DuckCelt®17 cell line (ECACC 09070703) and method for producing the Live-Attenuated human metapneumovirus-based vaccine platform METAVAC®. DuckCelt®-17 has been acquired by Vaxxel, a spin-off of the VirPath laboratory and Virnext. An exclusive worldwide license has been grant to Vaxxel for the use of METAVAC®.  This achievement is issued from a very fruitful collaboration with Dr. Guy Boivin’s team LVMC at the Centre de recherche du CHU de...

Our results support considering the clinical evaluation of favipiravir against Zika virus but they advocate against its use against SARS-CoV-2 infection. Our models of SARS-CoV-2 infection in reconstituted Human Airway Epithelium (MucilAir) were predictive again of the results obtained in the cynomolgus NHP model, demonstrating that favipiravir, even at doses up to 600 μM, has no antiviral efficacy against SARS-CoV-2.  Although our results are in contradiction with those obtained in...

The aim of this partnership is to develop innovative experimental methodologies and ambitious logistics for evaluating air treatment technologies and devices in atmospheres contaminated by complex infectious microbiological and virological mixtures. In particular, this Alliance will make it possible to develop mobile and deployable test benches of very large volume (up to 50 m3), enabling the implementation of experimental protocols reproducing real environmental conditions (classrooms, clean ro...

The aim of this strategic and commercial partnership is to address the major health, economic and societal challenges caused by environmental pollution of indoor air and confined spaces. CONIDIA and VirexpR are combining their respective expertise and logistics to offer a new range of services for assessing the performance of air treatment and respiratory protection technologies and devices in atmospheres contaminated by complex infectious microbiologic and virologic mixtures. This partnership w...

Virnext and VirPath laboratory are proud to be associated with Axo Science and EPIMOD companies as part of the SurVir public-private consortium, which aims to develop an automated platform for rapid detection of a wide range of respiratory pathogenic viruses. This public-private consortium has validated an initial proof of concept on various influenza A/B viruses and the Omicron variant of the SARS-CoV-2 virus. The second phase of the research programm will now be implemented in our BSL-2 and BS...

Cynbiose and VirNext have joined forces to offer a unique and innovative preclinical package of services for the evaluation of drugs, vaccines and antibodies candidates against (re)-emergent respiratory viruses, from in vitro screening to in vivo efficacy models of infections, including large animals. On the basis of a public-private partnership initiated in 2017, we have contributed to the evaluation of hundreds of candidates for respiratory viruses, including SARSCoV2 variants, cell lines, rec...